Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
出版年份 2023 全文链接
标题
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
作者
关键词
-
出版物
Lancet Haematology
Volume 10, Issue 8, Pages e600-e611
出版商
Elsevier BV
发表日期
2023-07-04
DOI
10.1016/s2352-3026(23)00117-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Conditioning Intensity and Peri-Transplant Flow Cytometric MRD Dynamics in Adult AML
- (2022) Gabrielle Paras et al. BLOOD
- Molecular profile of FLT3-mutated relapsed/refractory AML patients in the phase 3 ADMIRAL study of gilteritinib
- (2022) Catherine C. Smith et al. Blood Advances
- A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia
- (2022) Xiaoxia Chen et al. CANCER
- Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial
- (2022) Nikolaus Jahn et al. LEUKEMIA
- Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial
- (2022) Xin Xu et al. BMC Medicine
- Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia
- (2022) Tim Grob et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial
- (2022) Richard F. Schlenk et al. BLOOD
- Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
- (2021) Li Xuan et al. Journal of Hematology & Oncology
- FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions
- (2020) Ahmad I. Antar et al. LEUKEMIA
- Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
- (2020) Ali Bazarbachi et al. HAEMATOLOGICA
- Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data
- (2020) Sijian Yu et al. Journal of Hematology & Oncology
- Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia
- (2020) Iman Abou Dalle et al. Blood Cancer Journal
- Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)
- (2020) Andreas Burchert et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
- (2020) Li Xuan et al. LANCET ONCOLOGY
- Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia
- (2020) Richard T. Maziarz et al. BONE MARROW TRANSPLANTATION
- Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
- (2019) Li Xuan et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation
- (2018) Li Xuan et al. CANCER
- Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
- (2018) Nimitha R Mathew et al. NATURE MEDICINE
- Molecular Minimal Residual Disease in Acute Myeloid Leukemia
- (2018) Mojca Jongen-Lavrencic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Practical recommendations for reporting Fine-Gray model analyses for competing risk data
- (2017) Peter C. Austin et al. STATISTICS IN MEDICINE
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
- (2015) Madan H. Jagasia et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
- (2015) Christoph Röllig et al. LANCET ONCOLOGY
- Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
- (2014) Yi-Bin Chen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells
- (2013) Martin Franz Sprinzl et al. HEPATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started